X4 PHARMACEUTICALS INC. - COMMON STOCK

X4 Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host a Conference Call and Webcast on May 12, 2022

03 май 2022 06:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 май 2022 16:05:01 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting 2022

08 апр 2022 13:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Present at April Investor Conferences

04 апр 2022 08:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 апр 2022 16:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

17 мар 2022 06:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Announce Fourth Quarter 2021 Financial Results and Host a Conference Call and Webcast on March 17, 2022

08 мар 2022 08:00:03 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Present at March Investor Conferences

03 мар 2022 08:00:01 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 мар 2022 08:00:01 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 фев 2022 16:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Present at B. Riley Securities Oncology Investor Conference

19 янв 2022 08:00:01 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 янв 2022 16:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Presents New Clinical and Scientific Data at 2021 ASH Annual Meeting Supporting Broader Potential for Mavorixafor in the Treatment of Primary Immunodeficiencies

13 дек 2021 08:00:01 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Presents New Clinical Data at ASH 2021 Further Supporting Potential of Mavorixafor + Ibrutinib to Treat Patients with Double-Mutation Waldenström’s Macroglobulinemia

11 дек 2021 09:00:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Host Virtual Seminar “Understanding Primary Immunodeficiencies” to Highlight Broadening Market Opportunities for Mavorixafor

02 дек 2021 06:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 дек 2021 16:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in Stifel’s Virtual Healthcare Conference

10 ноя 2021 08:00:02 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Have Strong Presence at ASH 2021 with Seven Accepted Abstracts Highlighting New Clinical and Scientific Data; Company Reports Third Quarter Financial Results

04 ноя 2021 09:01:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 ноя 2021 16:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 4, 2021

25 окт 2021 08:00:01 Источник Nasdaq GlobeNewswire